Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963232 | 0.87 | KDM4E (0.62) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL14963235 | 0.87 | KDM4E (0.62) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL30987784 | 0.85 | KDM4E (0.86) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL433307 | 0.84 | KDM4E (0.58) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL3295915 | 0.84 | KDM4E (0.64) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL434624 | 0.82 | KDM4E (0.80) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL10482215 | 0.79 | MAPT (0.60) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL23998044 | 0.78 | KDM4E (0.73) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL3829818 | 0.78 | MAPT (0.58) | KDM4EKMT2AMEN1MAPTALOX15 | |
| SCHEMBL28919085 | 0.78 | KDM4E (0.56) | KDM4EKMT2AMEN1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131126-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | JSC GRINDEKS (LV) | 2013-05-23 | — | — | US | disclosed |
| US-20130131126-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | JSC GRINDEKS (LV) | 2013-05-23 | — | — | US | disclosed |
| US-20130131126-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | JSC GRINDEKS (LV) | 2013-05-23 | — | — | US | disclosed |
| EP-2593430-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | Grindeks (LV) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012010276-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | GRINDEKS (LV) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010276-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | GRINDEKS (LV) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131126-A1 | DERIVATIVES OF 1,4-DIHYDROPYRIDINE POSSESSING ANTIVIRAL EFFICACY | IFNAR1, SARS1, MAVS | KDM4E 43/4885KMT2A 717/4885MEN1 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.